These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31925920)

  • 1. Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma.
    Marr K; Ronsley R; Nadel H; Douglas K; Gershony S; Strahlendorf C; Davis JH; Deyell RJ
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28167. PubMed ID: 31925920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
    Balzarotti M; Brusamolino E; Angelucci E; Carella AM; Vitolo U; Russo E; Congiu A; Gotti M; Massidda S; Botto B; Annechini G; Spina M; Re A; Zilioli VR; Merli F; Salvi F; Stelitano C; Bonfichi M; Rodari M; Murru R; Magagnoli M; Anastasia A; Mazza R; Giordano L; Santoro A
    Leuk Lymphoma; 2016 Oct; 57(10):2375-81. PubMed ID: 26879066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.
    Suyanı E; Sucak GT; Akı ŞZ; Yeğin ZA; Özkurt ZN; Yağcı M
    Ann Hematol; 2011 Jun; 90(6):685-91. PubMed ID: 21072518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.
    Santoro A; Magagnoli M; Spina M; Pinotti G; Siracusano L; Michieli M; Nozza A; Sarina B; Morenghi E; Castagna L; Tirelli U; Balzarotti M
    Haematologica; 2007 Jan; 92(1):35-41. PubMed ID: 17229633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report.
    Trippett TM; Schwartz CL; Guillerman RP; Gamis AS; Gardner S; Hogan S; London WB; Chen L; de Alarcon P
    Pediatr Blood Cancer; 2015 Jan; 62(1):60-4. PubMed ID: 25308760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
    Castagna L; Magagnoli M; Balzarotti M; Sarina B; Siracusano L; Nozza A; Todisco E; Bramanti S; Mazza R; Russo F; Timofeeva I; Santoro A
    Am J Hematol; 2007 Feb; 82(2):122-7. PubMed ID: 17019686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
    Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
    Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
    Santoro A; Mazza R; Pulsoni A; Re A; Bonfichi M; Zilioli VR; Salvi F; Merli F; Anastasia A; Luminari S; Annechini G; Gotti M; Peli A; Liberati AM; Di Renzo N; Castagna L; Giordano L; Carlo-Stella C
    J Clin Oncol; 2016 Sep; 34(27):3293-9. PubMed ID: 27382096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma.
    Abuelgasim KA; Alzahrani M; Alsharhan Y; Khairi M; Hommady M; Gmati G; Salama H; Ali O; Alahmari B; Masuadi EM; Alaskar A; Alhejazi A; Damlaj M
    Bone Marrow Transplant; 2019 Jul; 54(7):1168-1172. PubMed ID: 30700792
    [No Abstract]   [Full Text] [Related]  

  • 10. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients.
    Magagnoli M; Spina M; Balzarotti M; Timofeeva I; Isa L; Michieli M; Capizzuto R; Morenghi E; Castagna L; Tirelli U; Santoro A
    Bone Marrow Transplant; 2007 Dec; 40(11):1019-25. PubMed ID: 17906705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients.
    Gokmen A; Sahin U; Soydan E; Gokgoz Z; Okcu MK; Ozan U; Arslan O; Ilhan O; Ozcan M
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e885-e892. PubMed ID: 35927182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine and vinorelbine as a salvage regimen for relapse in Hodgkin lymphoma after autologous hematopoietic stem cell transplantation.
    Ozkaynak MF; Jayabose S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):107-13. PubMed ID: 15160509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
    Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G
    Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed/refractory hodgkin's lymphoma.
    Ganesan P; Mehra N; Joel A; Radhakrishnan V; Dhanushkodi M; Perumal Kalayarasi J; Kannan K; Ganesan TS; Sagar TG
    Leuk Res; 2019 Sep; 84():106188. PubMed ID: 31325732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.
    Bai B; Huang HQ; Cai QQ; Wang XX; Cai QC; Lin ZX; Gao Y; Xia Y; Bu Q; Guo Y
    Med Oncol; 2013 Mar; 30(1):350. PubMed ID: 23329307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
    Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
    Ann Oncol; 2006 May; 17 Suppl 4():iv25-30. PubMed ID: 16702181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients.
    Sibon D; Ertault M; Al Nawakil C; de Bazelaire C; Franchi P; Brière J; de Kerviler E; Beranger N; Thieblemont C; Brice P
    Br J Haematol; 2011 Apr; 153(2):191-8. PubMed ID: 21385169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience.
    Batgi H; Başcı S; Dal MS; Kızıl Çakar M; Uncu Ulu B; Yiğenoğlu TN; Özcan N; Kılınç A; Merdin A; Yıldız J; Bakırtaş M; Şahin D; Darçın T; İskender D; Baysal NA; Altuntaş F
    Turk J Med Sci; 2021 Apr; 51(2):685-692. PubMed ID: 33237657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.